The concentrationsof free fucose and other sugars in urine of cancer patients and healthy subjects were analyzed by high-performance liquid chromatography. After the urine samples were dried, we coupled the sugars in the residue with 2-aminopyridine to be detected as fluorescent derivatives. We then analyzed the pyrldylamino derivatives ofthe sugars with an anion-exchange column and borate buffer. The difference between cancer patients and healthy subjects for the mean concentrations of fucose corrected for creatinine was significant (P <0.001). We checked the relationship between the concentrations of other sugars and the presence of cancer. This method is highly sensitive, and neither a cleanup procedure before labeling nor purification before injection intothe column is needed. Not only fucose but also other sugars can be detected simultaneously, so this method should be usefulfor studyingany changes in sugars in urine in various diseases. We used a Model LC-6A (Shimadzu Corp., Kyoto, Japan) liquid chromatograph equipped with a Model 7125 injector (Rheodyne, Cotati, CA) and a Model F-1050 (Hitachi, Tokyo, Japan) fluorescence spectrophotometer.
L-Fucose is usually located at the nonreducing terminal of the sugar chains of glycoconjugates
(1).
This position makes it likely that L-fucose is important for the biological functions of the sugar chains found in some blood antigens (2, 3). Some reports describe the relationship between the fucose concentrations in body fluids and various diseases (4) (5) (6) (7) (8) (9) , but the metabolism of fucose and many other monosaccharides in humans is little understood.
Gas-liquid chromatography has been commonly used for monosaccharide analysis; however, the samples must be highly purified before such analyses. Therefore, for the analysis of crude samples such as body fluids, a tedious purification procedure is required, and the sensitivity is still low (at the nanomole level). We used a Model LC-6A (Shimadzu Corp., Kyoto, Japan) liquid chromatograph equipped with a Model 7125 injector (Rheodyne, Cotati, CA) and a Model F-1050 (Hitachi, Tokyo, Japan) fluorescence spectrophotometer.
The columns used were a 4.6 x 150 mm Palpak 1rpe A column (Takara Shuzo Co., Ltd., Kyoto, Japan), packed with a porous, quaternary amine-type resin, and a 4.6 x 250 mm Ultrasphere-ODS (octadecylsilyl) column (reversed-phase; Beckman Instruments, Inc., Fullerton, CA). Assay of creatinine. A commercial kit (Creatinine-HA Test 7150; Wako) (11) was used to assay creatinine in urine according to the manufacturer's directions. When picric acid is added to a urine sample, it condenses with creatinine in the urine, and the newly formed molecules turn the sample orange. The concentration of creatinine is assayed by the absorbance.
Assay of fucose. Urine samples were pyridyinminated as described elsewhere (10). In brief, 2 pL of urine was placed in a glass tube and evaporated.To the residue we added 7 L of a coupling reagent (a mixture of 1.00 g of 2-aminopyridine, 0.47 niL of acetic acid, and 0.60 mL of methanol) and heated this at 90 #{176}C for 15 mm. Excess reagents were removed by evaporation under a stream of nitrogen gas at 60#{176}C for 20 mm. We then added 10 pL of a reducing reagent, prepared just before use by mixing 59 mg of borane-dimethyissnine complex and 1 mL of acetic acid. After heating the mixture at 90#{176}C for 30 mm, we dried it twice with 30 pL of toluene under a stream of nitrogen gas at 40#{176}C for 10 mm each time to remove excess reagent& The residue was dissolved in 500 1L of water, and 5 pL of the solution was analyzed by HPLC with the Palpak column. Themobile phase was a mixture of 0.7 mol/L boric acid (adjusted to pH 9.0 with potassium hydroxide) and acetonitzile ( detection of pyridylamino (PA-derivatized) sugars, we used an excitation wavelength of 310 nm and an emission wavelength of 380 nm.
Results

Analytical Performance
Standard curve for PA-fucose. To check whether proteins and other compounds in urine interfered with the quantification of fucose, we constructed a standard curve as follows. Fucose was added to a urine sample so that the added amount would give a concentration of 0.01 to 1 .00 mmol/L. The mixture was pyridylaminated and analyzed by HPLC as described above. The original amount of fucose in the urine sample was subtracted from the total amount found, and the difference was plotted against the amount of added fucose. Linearity between the peak height (and also the peak area) and the concentration of fucose was satisfactory (Figure 1) .
Recently we reported an improved method for the pyridylamination of sialyl sugar chains (12). Desialylation in that procedure was <3%, evidence that the hydrolysis of monosaccharides is negligible under those reaction conditions. Because the reaction conditions for sugar chains and monosaccharides are slightly different, we checked whether fucose was hydrolyzed under the conditions used here; again, we found that hydrolysis was negligible (data not shown).
Assay variation.
We pyridylaminated and analyzed three samples with a low, medium, or high concentration of fucose five times each. The CV was 4.4%, 2.0%, and 2.4%, respectively.
Analytical recovery of PA-fucose. We added 0.1 or 1.0 nmol of fucose to three samples with a low, medium, or high concentration of fucose. Analytical recovery ranged from 97% to 106%, showing that urinary fucose could be analyzed quantitatively. Our method for assays of fucose was based on this, after we made the following checks with samples chosen, without conscious bias, from our healthy subjects. The correlation between the fucose/ creatinine ratio of 24-h specimens and that of untimed samples was good (r = 0.985; data not shown). The 
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Liver cancer the between-day variations in the fucose values of the same healthy man and woman shows that results were all within the normal range (Figure 2 ).
Fucose concentrations
in urine from cancer patients and healthy subjects. We used this method to assay fucose in urine from 60 cancer patients and 10 healthy subjects. Figure 3 shows the elution pattern of a standard solution of PA-sugars and of urine samples from a healthy subject and from a cancer patient. The amount of fucose was calculated by the peak height of PA-fucose. The fucose values (corrected for the concentration of creatinine)
for each group of subjects are shown in Figure 4 . The fucose values ranged from 27 to 498 pznol/g for the cancer patients and from 4 to 90 moI/g for the healthy subjects. Of the 60 cancer patients, 42(70%) had higher values than the cutoff value of 103 pznol/L (mean +2 SD of values in healthy subjects). This demonstrates a close relationship between cancer and the concentrations of urinary free fucose (P <0.001, Student's t-test In conclusion, our method is useful because fucose and other sugars in crude urine samples can be assayed simultaneously at the picomole level, without any cleanup procedure before labeling. Our results suggest that this method could be of use in studies of the relationship between sugars in urine and diseases, including diseases that develop because of an error in the metabolism of sugars.
